Home LiteratureArticle Details
PMID: 18593947 Published · ppublish English Journal Article Research Support, N.I.H., Extramural

Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells.

Cancer research ·Vol. 68 ·No. 13 ·2008-07-01 ·Pages 5439-49

Serafini P, Mgebroff S, Noonan K, Borrello I

Abstract

Tumor-induced T-cell tolerance is a major mechanism that facilitates tumor progression and limits the efficacy of immune therapeutic interventions. Regulatory T cells (Treg) play a central role in the induction of tolerance to tumor antigens, yet the precise mechanisms regulating its induction in vivo remain to be elucidated. Using the A20 B-cell lymphoma model, here we identify myeloid-derived suppressor cells (MDSC) as the tolerogenic antigen presenting cells capable of antigen uptake and presentation to tumor-specific Tregs. MDSC-mediated Treg induction requires arginase but is transforming growth factor-beta independent. In vitro and in vivo inhibition of MDSC function, respectively, with NOHA or sildenafil abrogates Treg proliferation and tumor-induced tolerance in antigen-specific T cells. These findings establish a role for MDSCs in antigen-specific tolerance induction through preferential antigen uptake mediating the recruitment and expansion of Tregs. Furthermore, therapeutic interventions, such as in vivo phosphodiesterase 5-inhibition, which effectively abrogate the immunosuppressive role of MDSCs and reduce Treg numbers, may play a critical role in delaying and/or reversing tolerance induction.

MeSH Terms
Animals Antigens, Neoplasm/metabolism CD11b Antigen/metabolism Cell Proliferation Cells, Cultured Disease Progression Genes, T-Cell Receptor Immune Tolerance/physiology Lymphoma, B-Cell/immunology,metabolism Mice Mice, Inbred BALB C Mice, Transgenic Myeloid Cells/metabolism,physiology Phosphodiesterase Inhibitors/pharmacology Piperazines/pharmacology Purines/pharmacology Receptors, Cell Surface/metabolism Sildenafil Citrate Sulfones/pharmacology T-Lymphocytes, Regulatory/metabolism,physiology Tumor Escape/immunology
Chemicals
Antigens, Neoplasm CD11b Antigen Il4ra protein, mouse Phosphodiesterase Inhibitors Piperazines Purines Receptors, Cell Surface Sulfones Sildenafil Citrate
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Serafini Paolo
Department of Microbiology and Immunology, Dodson Interdisciplinary Immunotherapy Institute, University of Miami, School of Medicine, Miami, Florida 33136, USA. [email protected]
Mgebroff Stephanie
Noonan Kimberly
Borrello Ivan
References (42)
42 references, click to expand
  1. Follicular lymphomas can be induced to present alloantigen efficiently: a conceptual model to improve their tumor immunogenicity.
    Proc Natl Acad Sci U S A. 1995 Aug 29;92(18):8200-4 PMID: 7545296
  2. Recognition of immunoglobulin idiotypes by thymus-derived lymphocytes.
    Proc Natl Acad Sci U S A. 1975 Jun;72(6):2357-60 PMID: 49059
  3. Induction of antigen-specific T cell anergy: An early event in the course of tumor progression.
    Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83 PMID: 9448305
  4. Growth factor-induced mobilization of dendritic cells in kidney and liver of rhesus macaques: implications for transplantation.
    Transplantation. 2007 Mar 15;83(5):656-62 PMID: 17353790
  5. Therapeutic effect of idiotype-specific CD4+ T cells against B-cell lymphoma in the absence of anti-idiotypic antibodies.
    Blood. 2003 Jul 15;102(2):605-12 PMID: 12649166
  6. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells.
    J Immunol. 2005 Feb 15;174(4):1841-50 PMID: 15699110
  7. B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells.
    Proc Natl Acad Sci U S A. 1989 Jan;86(1):282-6 PMID: 2492101
  8. Differential modulation of CD4 and CD8 T-cell proliferation by induction of nitric oxide synthesis in antigen presenting cells.
    Transplantation. 2002 Sep 27;74(6):836-45 PMID: 12364865
  9. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines.
    Blood. 2006 Jan 15;107(2):628-36 PMID: 16179369
  10. Modulation of tryptophan catabolism by human leukemic cells results in the conversion of CD25- into CD25+ T regulatory cells.
    Blood. 2007 Apr 1;109(7):2871-7 PMID: 17164341
  11. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host.
    Cancer Res. 2006 Jan 15;66(2):1123-31 PMID: 16424049
  12. Inhibition of calcium signalling in murine splenocytes by polyamines: differential effects on CD4 and CD8 T-cells.
    Biochem J. 1993 Apr 15;291 ( Pt 2):375-81 PMID: 8097908
  13. Derangement of immune responses by myeloid suppressor cells.
    Cancer Immunol Immunother. 2004 Feb;53(2):64-72 PMID: 14593498
  14. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function.
    J Exp Med. 2006 Nov 27;203(12):2691-702 PMID: 17101732
  15. Myeloma proteins as tumor-specific antigens.
    Transplant Proc. 1975 Jun;7(2):209-14 PMID: 48299
  16. Phosphorylation of the survival kinase Akt by superoxide is dependent on an ascorbate-reversible oxidation of PTEN.
    Free Radic Biol Med. 2007 Apr 15;42(8):1178-92 PMID: 17382199
  17. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.
    Nat Med. 2007 Jul;13(7):828-35 PMID: 17603493
  18. Regulation of immune responses by L-arginine metabolism.
    Nat Rev Immunol. 2005 Aug;5(8):641-54 PMID: 16056256
  19. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression.
    Blood. 2001 Aug 15;98(4):1070-7 PMID: 11493453
  20. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells.
    Blood. 2000 Oct 15;96(8):2828-33 PMID: 11023518
  21. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes.
    J Immunol. 2000 Dec 15;165(12):6723-30 PMID: 11120790
  22. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells.
    J Immunol. 2004 May 1;172(9):5287-96 PMID: 15100267
  23. Lymphoma.
    Curr Opin Oncol. 1997 Sep;9(5):389-91 PMID: 9327215
  24. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation.
    J Exp Med. 2005 Oct 3;202(7):919-29 PMID: 16186184
  25. Nitric oxide-independent CTL suppression during tumor progression: association with arginase-producing (M2) myeloid cells.
    J Immunol. 2003 May 15;170(10):5064-74 PMID: 12734351
  26. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway.
    Nat Immunol. 2000 Dec;1(6):515-20 PMID: 11101874
  27. Dendritic cells and tumor microenvironment: a dangerous liaison.
    Immunol Invest. 2006;35(3-4):459-83 PMID: 16916762
  28. Mechanisms and functional significance of tumour-induced dendritic-cell defects.
    Nat Rev Immunol. 2004 Dec;4(12):941-52 PMID: 15573129
  29. Effects of L-arginine on the proliferation of T lymphocyte subpopulations.
    JPEN J Parenter Enteral Nutr. 2001 Jan-Feb;25(1):23-9 PMID: 11190986
  30. IL-4-induced arginase 1 suppresses alloreactive T cells in tumor-bearing mice.
    J Immunol. 2003 Jan 1;170(1):270-8 PMID: 12496409
  31. Ia antigen-bearing B cell tumor lines can present protein antigen and alloantigen in a major histocompatibility complex-restricted fashion to antigen-reactive T cells.
    J Exp Med. 1982 Feb 1;155(2):445-59 PMID: 6460073
  32. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion.
    J Immunol. 2005 Apr 15;174(8):4880-91 PMID: 15814715
  33. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.
    J Immunol. 2005 Jan 15;174(2):636-45 PMID: 15634881
  34. Conversion of tumor-specific CD4+ T-cell tolerance to T-cell priming through in vivo ligation of CD40.
    Nat Med. 1999 Jul;5(7):780-7 PMID: 10395323
  35. Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.
    J Exp Med. 2003 Dec 1;198(11):1741-52 PMID: 14657224
  36. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.
    J Clin Invest. 2006 Oct;116(10):2777-90 PMID: 17016559
  37. In vivo disruption of tolerogenic cross-presentation mechanisms uncovers an effective T-cell activation by B-cell lymphomas leading to antitumor immunity.
    Blood. 2006 Apr 1;107(7):2871-8 PMID: 16339406
  38. Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.
    Blood. 2000 Dec 1;96(12):3838-46 PMID: 11090068
  39. Tolerance and cancer: a critical issue in tumor immunology.
    Crit Rev Oncog. 1996;7(5-6):433-56 PMID: 9467666
  40. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance.
    J Immunol. 2007 Feb 15;178(4):2155-62 PMID: 17277120
  41. Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.
    Cancer Res. 2004 Aug 15;64(16):5839-49 PMID: 15313928
  42. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression.
    Semin Cancer Biol. 2006 Feb;16(1):53-65 PMID: 16168663
Article Info
Journal
Cancer research
Abbr.
Cancer Res
ISSN
1538-7445
Published
2008-07-01
Pages
5439-49
Language
English
Region
United States
NLM ID
2984705R
PMCID
PMC2887390
Subset
IM
Grants
NCI NIH HHS · R01 CA124996 · United States
NCI NIH HHS · R01 CA124996-02 · United States
NCI NIH HHS · 1 R01 CA124996-01A1 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]